HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer - Wikidata - awgldk - TriplyDB

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

http://www.wikidata.org/entity/Q34104074

about

Molecular targeted therapy for the treatment of gastric cancer Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.MET receptor is a potential therapeutic target in high grade cervical cancer Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.Isothiocyanatostilbenes as novel c-Met inhibitors.Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?miR-206-3p Inhibits 3T3-L1 Cell Adipogenesis via the c-Met/PI3K/Akt Pathway.The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma.Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer.Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.c-Met and miRs in Cancer.Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.

P2860

Q28072433-D91215F2-8C9E-4458-A19D-1694EF2E73FB Q28081193-0D7DF7E8-6712-42B0-B6BD-23545805E894 Q33604480-727BDB3F-89CC-4807-8C72-B75363A82A46 Q35832923-B522904F-22F4-4C17-AE4B-BB6F4ECD6C07 Q36414376-1E8CB0DA-521A-4C7F-9A5F-58862061717C Q36414504-4CDCC9A1-57B6-4FD4-943B-DE4728A2FAC8 Q36562316-CC781ABF-810F-4142-BCD0-FC2B855A24F0 Q36979335-DF64A727-F1DD-4620-8BA9-76A86C667499 Q37109724-AA68AEED-64D3-45C4-947E-EC8A1A85FAE3 Q38476204-180236E5-2961-4CE3-A8DD-D3AB1EA710B7 Q38679259-92800B56-53A7-41F8-80E7-964029970A22 Q38806970-4B823EA3-004F-4D2E-87F1-A18F58A7A779 Q38816624-FE55548E-B939-4196-81DC-CADEE873F111 Q49887893-1822391D-09AB-4007-9640-2E101B59DAFC Q51158233-E0E18532-D05C-4224-9E81-07E41ACBE6FD Q52858895-782E4BC1-C53B-4521-99F1-DDF9A141879D

P2860

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

http://www.wikidata.org/entity/Q34104074

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

@ast

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

@en

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

@nl

type

label

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

@ast

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

@en

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

@nl

prefLabel

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

@ast

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

@en

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

@nl

P1433

Q34104074-92A13847-CEDB-493A-A377-0A7F78E31200

P1476

Q34104074-D47F3A9D-10FE-43DE-A541-8DE536CF3852

P2093

Q34104074-4EB5A073-C616-4930-9C90-58494F3A36CE

Q34104074-6119EDA2-5AD9-4294-8DE7-C74513370538

Q34104074-670A8B82-5CBD-4FBE-8159-06F67D635B8F

Q34104074-7B8A44C4-C27B-43A7-99EA-5C4E79EF2D85

Q34104074-84DAF7DF-5307-4F41-B8A1-802CE446B8B3

Q34104074-88916545-B234-490C-BE0D-3807E595AFF6

Q34104074-97AF7200-6F31-4DEF-B1C6-ECFB509AABD3

Q34104074-98D3B2F7-5D5C-4348-AB21-89BEAFE6806C

Q34104074-A52BCA18-FF72-46CA-8085-C8D115D85F28

Q34104074-BA687C30-8356-400A-8EEE-361563DFA589

P2860

Q34104074-039F14AE-69DD-496E-B24F-369E71093399

Q34104074-1EF8866E-91A6-492D-AFB7-2A01004FD47E

Q34104074-208D6C3C-0640-41F9-9D9D-39B578B6D03F

Q34104074-2B64B299-7219-4840-86AC-2EEB20571414

Q34104074-2CB141EB-EA5E-464D-9218-DC54C48D6AEC

Q34104074-3D667E51-0270-46A2-BE24-CF4C83A1271D

Q34104074-463C2AA1-0CF3-4DD1-861F-83640E85CCB9

Q34104074-495D5E50-5115-40A8-9F1F-9E7DD6BC52B9

Q34104074-4F8A83EB-84EA-42EE-A0DC-7BD704BE097B

Q34104074-5905FB72-E5D3-4816-8D6E-F8FD10BFD54E

P304

Q34104074-E4EC50FA-EF3B-4289-BEF6-53D3913D9D48

P31

Q34104074-9CF589AC-B980-4953-83CE-48F2DC8984AF

P356

Q34104074-021F90EA-A79B-4480-BA47-B2C62A9F1666

P407

Q34104074-D805F282-3D79-4A33-963C-D1E6FD2918F2

P433

Q34104074-A76FF182-FFE0-4704-B0DD-FE988173B6C7

P478

Q34104074-F6D0EC9E-024A-4B3F-A0A8-5846732511A9

P577

Q34104074-B50DF6A1-5F59-4B98-AFB0-597F06A759D3

P698

Q34104074-8D4455D1-5842-4B27-9442-65C11EE8BEE9

P921

Q34104074-601710A5-40BB-4A97-9982-CED6A7433BF2

P932

Q34104074-90934754-4A18-480E-AE45-D59A28A69FF7

P356

ONCOTARGET.2049

P1433

P1476

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

@en

P2093

Cristiano Ferlini

http://www.w3.org/2001/XMLSchema#string

Giovanni Scambia

http://www.w3.org/2001/XMLSchema#string

Marco Petrillo

http://www.w3.org/2001/XMLSchema#string

Marisa Mariani

http://www.w3.org/2001/XMLSchema#string

Mark McHugh

http://www.w3.org/2001/XMLSchema#string

Mirko Andreoli

http://www.w3.org/2001/XMLSchema#string

Paul Fiedler

http://www.w3.org/2001/XMLSchema#string

Shiquan He

http://www.w3.org/2001/XMLSchema#string

Shohreh Shahabi

http://www.w3.org/2001/XMLSchema#string

Steven Sieber

http://www.w3.org/2001/XMLSchema#string

P2860

MiR-200c and HuR in ovarian cancer

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

An improved single-cell cDNA amplification method for efficient high-density oligonucleotide microarray analysis

Integrated genomic analyses of ovarian carcinoma

Global quantification of mammalian gene expression control

HuR regulates beta-tubulin isotype expression in ovarian cancer

Molecular mechanisms of patupilone resistance

Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate

High throughput gene expression measurement with real time PCR in a microfluidic dynamic array

c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.

P304

4855-4867

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2049

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24952592

http://www.w3.org/2001/XMLSchema#string

P921

P932

4148105

http://www.w3.org/2001/XMLSchema#string